Active 0 6 0 6 O
autoimmune 7 17 7 17 B-chronic_disease
disease 18 25 18 25 I-chronic_disease

Age 0 3 26 29 B-age
: 3 4 29 30 O
3 5 6 31 32 B-lower_bound
- 6 7 32 33 O
21 7 9 33 35 B-upper_bound
years 10 15 36 41 I-upper_bound

DIPG 0 4 42 46 B-cancer
patients 5 13 47 55 O
enrolled 14 22 56 64 O
to 23 25 65 67 O
Group 26 31 68 73 O
3b 32 34 74 76 O
must 35 39 77 81 O
not 40 43 82 85 O
have 44 48 86 90 O
been 49 53 91 95 O
previously 54 64 96 106 O
treated 65 72 107 114 O
with 73 77 115 119 O
radiation 78 87 120 129 B-treatment
or 88 90 130 132 O
any 91 94 133 136 O
medical 95 102 137 144 B-treatment
therapy 103 110 145 152 I-treatment

Lansky 0 6 153 159 B-clinical_variable
or 7 9 160 162 O
Karnofsky 10 19 163 172 B-clinical_variable
performance 20 31 173 184 I-clinical_variable
status 32 38 185 191 I-clinical_variable
score 39 44 192 197 I-clinical_variable
must 45 49 198 202 O
be 50 52 203 205 O
> 53 54 206 207 O
50 55 57 208 210 B-lower_bound
% 57 58 210 211 I-lower_bound

MRI 0 3 212 215 B-treatment
confirmation 4 16 216 228 O
of 17 19 229 231 O
tumor 20 25 232 237 B-cancer
progression 26 37 238 249 O
or 38 40 250 252 O
regrowth 41 49 253 261 O

Patients 0 8 262 270 O
previously 9 19 271 281 O
treated 20 27 282 289 O
with 28 32 290 294 O
temozolomide 33 45 295 307 B-treatment
, 45 46 307 308 O
cyclophosphamide 47 63 309 325 B-treatment
, 63 64 325 326 O
and/or 65 71 327 333 O
etoposide 72 81 334 343 B-treatment
are 82 85 344 347 O
eligible 86 94 348 356 O
for 95 98 357 360 O
enrollment 99 109 361 371 O

Patients 0 8 372 380 O
with 9 13 381 385 O
a 14 15 386 387 O
radiographic 16 28 388 400 O
diagnosis 29 38 401 410 O
or 39 41 411 413 O
histologically 42 56 414 428 O
proven 57 63 429 435 O
diagnosis 64 73 436 445 O
of 74 76 446 448 O
diffuse 77 84 449 456 B-cancer
intrinsic 85 94 457 466 I-cancer
pontine 95 102 467 474 I-cancer
glioma 103 109 475 481 I-cancer
( 110 111 482 483 I-cancer
DIPG 111 115 483 487 I-cancer
) 115 116 487 488 I-cancer

Patients 0 8 489 497 O
with 9 13 498 502 O
baseline 14 22 503 511 O
QTc 23 26 512 515 B-clinical_variable
interval 27 35 516 524 I-clinical_variable
of 36 38 525 527 O
more 39 43 528 532 O
than 44 48 533 537 O
470 49 52 538 541 B-lower_bound
msec 53 57 542 546 I-lower_bound
at 58 60 547 549 O
study 61 66 550 555 O
entry 67 72 556 561 O
, 72 73 561 562 O
and 74 77 563 566 O
patients 78 86 567 575 O
with 87 91 576 580 O
congenital 92 102 581 591 B-chronic_disease
long 103 107 592 596 I-chronic_disease
QTc 108 111 597 600 I-chronic_disease
syndrome 112 120 601 609 I-chronic_disease

Patients 0 8 610 618 O
with 9 13 619 623 O
metastatic 14 24 624 634 B-cancer
disease 25 32 635 642 I-cancer
are 33 36 643 646 O
eligible 37 45 647 655 O
for 46 49 656 659 O
enrollment 50 60 660 670 O

Seizure 0 7 671 678 B-chronic_disease
disorders 8 17 679 688 I-chronic_disease
must 18 22 689 693 O
be 23 25 694 696 O
well 26 30 697 701 O
controlled 31 41 702 712 O
on 42 44 713 715 O
antiepileptic 45 58 716 729 B-treatment
medication 59 69 730 740 I-treatment

histologically 0 14 741 755 O
proven 15 21 756 762 O
initial 22 29 763 770 O
diagnosis 30 39 771 780 O
of 40 42 781 783 O
high 43 47 784 788 B-cancer
- 47 48 788 789 I-cancer
grade 48 53 789 794 I-cancer
glioma 54 60 795 801 I-cancer
( 61 62 802 803 O
WHO 62 65 803 806 O
grade 66 71 807 812 O
III 72 75 813 816 O
and 76 79 817 820 O
IV 80 82 821 823 O
) 82 83 823 824 O
, 83 84 824 825 O
ependymoma 85 95 826 836 B-cancer
, 95 96 836 837 O
medulloblastoma 97 112 838 853 B-cancer
, 112 113 853 854 O
or 114 116 855 857 O
other 117 122 858 863 O
primary 123 130 864 871 B-cancer
central 131 138 872 879 I-cancer
nervous 139 146 880 887 I-cancer
system 147 153 888 894 I-cancer
tumor 154 159 895 900 I-cancer

histologically 0 14 901 915 O
proven 15 21 916 922 O
initial 22 29 923 930 O
diagnosis 30 39 931 940 O
of 40 42 941 943 O
primary 43 50 944 951 B-cancer
malignant 51 60 952 961 I-cancer
brain 61 66 962 967 I-cancer
tumor 67 72 968 973 I-cancer
, 72 73 973 974 O
with 74 78 975 979 O
no 79 81 980 982 O
known 82 87 983 988 O
curative 88 96 989 997 O
treatment 97 106 998 1007 B-treatment
options 107 114 1008 1015 O

